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Abstract
First line therapy for colorectal cancer (CRC) is usually fluoropyrimidine monotherapy 
and oxaliplatin, or irinotecan-based therapy. Additionally, targeted therapies such as 
bevacizumab, aflibercept, ramucirumab, regorafenib, cetuximab and panitumumab are 
indicated in combination with chemotherapy in metastatic CRC. Resistance of CRC to 
treatment is the principal rationale for treatment failure. Resistance can be intrinsic (pri-
mary resistance) or acquired (secondary resistance). Here, we discuss the classical model 
of resistance, which focuses primarily on mechanisms involving alterations in drug 
metabolism, increased drug efflux, secondary mutations in drug targets, inactivation of 
apoptotic pathways, p53 and DNA damage repair. Other resistance mechanisms, includ-
ing the Warburg effect, cancer stem cells, intra-tumor heterogeneity and pharmacoepig-
enomic mechanisms will also be discussed. We conclude the chapter with a systems 
medicine approach to predict response to treatment for the discovery and validation of 
predictive biomarkers that are urgently needed.
Keywords: colorectal cancer, chemotherapy, targeted therapy, intrinsic resistance, 
acquired resistance, predictive biomarkers
1. Introduction
The mainstay of colorectal cancer (CRC) treatment is curative surgery, although in some cases 
patients are administered neo-adjuvant therapy. Surgery is usually followed by adjuvant ther-
apy in patients presenting with Stage III and Stage IV disease. Additionally, adjuvant therapy 
is sometimes administered to high risk stratified Stage II patients. Adjuvant treatment for stage 
III CRC patients consists of chemotherapy including 5-fluorouracil (5-FU), oxaliplatin and 
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capecitabine—usually administered combination therapy [1]. Patients having advanced CRC 
are frequently treated with targeted therapy in combination with chemotherapy, or as a single 
agent, and more recently with immunotherapy (Table 1). The rationale for using combination 
therapy is to avoid treatment resistance, promote a synergistic effect and reduce potential toxic-
ity (refer to Table 2).
Therapeutic agent Class Colorectal cancer indications Date of 
first launch 
worldwide 
[1–6]
5-Fluorouracil 
(5-FU)
Antimetabolite, 
pyrimidine analogue
Used as a single agent or in combination 1962
Epirubicin Cytotoxic antibiotics Used as a single agent or in combination 1984
Irinotecan Topoisomerase I 
inhibitor
1. Indicated for the treatment of mCRC:
 •  in combination with 5-FU and folinic acid in 
chemotherapy naïve patients
 •  as a single agent in patients who have failed a 
5-FU-based regimen
2.  In combination with cetuximab is indicated for the 
treatment of patients with EGFR-expressing KRAS 
wild-type mCRC, who had not received prior 
treatment for metastatic disease or after failure of 
irinotecan-including cytotoxic therapy
3.  In combination with 5-FU, folinic acid and 
bevacizumab is indicated for first-line treatment of 
patients with mCRC
4.  In combination with capecitabine with or without 
bevacizumab is indicated for first-line treatment of 
patients with mCRC
1994
Oxaliplatin Platinum derivative, 
alkylating agent
Oxaliplatin in combination with 5-FU and folinic acid 
is indicated for:
1.  adjuvant treatment of stage III colon cancer after 
complete resection of primary tumor
2. treatment of mCRC
1996
Raltitrexed Antimetabolite Palliative treatment of advanced colorectal cancer 
where 5-FU and folinic acid-based regimens are either 
not tolerated or inappropriate
1996
Capecitabine Antimetabolite 1. Used as a single agent or in combination
2.  Used for the adjuvant treatment of stage III colon 
cancer patients
3. Used in mCRC
1998
Cetuximab Monoclonal 
antibody, EGFR 
inhibitor
Indicated for the treatment of patients with EGFR-
expressing, RAS wt mCRC:
•  in combination with irinotecan-based 
chemotherapy
• in first-line in combination with FOLFOX
•  as a single agent in patients who have failed 
oxaliplatin- and irinotecan-based therapy and who 
are intolerant to irinotecan
2003
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Therapeutic agent Class Colorectal cancer indications Date of 
first launch 
worldwide 
[1–6]
Bevacizumab Monoclonal 
antibody, VEGF 
inhibitor
In combination with fluoropyrimidine-based 
chemotherapy is indicated for treatment of mCRC
2004
Panitumumab Monoclonal 
antibody, EGFR 
inhibitor
Indicated for the treatment of wt RAS mCRC:
1. first-line in combination with FOLFOX or FOLFIRI
2.  second-line in combination with FOLFIRI for patients 
who have received first-line fluoropyrimidine-based 
chemotherapy (excluding irinotecan)
3.  monotherapy after failure of fluoropyrimidine-, 
oxaliplatin-, and irinotecan-containing 
chemotherapy regimens
2006
Regorafenib Angiogenesis 
inhibitor, tyrosine 
kinase inhibitor
mCRC patients who have been previously treated with, 
or are not considered candidates for available therapies
2013
Aflibercept Angiogenesis 
inhibitor, tyrosine 
kinase inhibitor
In combination with FOLFIRI is indicated in 
mCRC that is resistant to or has progressed after an 
oxaliplatin-containing regimen
2013
Trifluridine/
tipiracil 
hydrochloride
Antimetabolite Treatment of mCRC patients who have been previously 
treated with, or are not considered candidates for 
available therapies
2015
Pembrolizumab Anti-PD1 
immunotherapy
Unresectable or metastatic, MSI-H or dMMR CRC 
that has progressed following treatment with a 
fluoropyrimidine, oxaliplatin, and irinotecan
2017
Table 1. Colorectal cancer drugs currently on the market.
Combination regimens Therapeutic agents
deGramont/modified de Gramont 5-Fluorouracil, folinic acid
FOLFIRINOX Folinic acid, 5-fluorouracil, irinotecan, oxaliplatin
FOLFIRI Folinic acid, 5-fluorouracil, irinotecan
FOLFOX Folinic acid, 5-fluorouracil, oxaliplatin
XELOX Oxaliplatin, capecitabine
FOLFIRI + cetuximab Folinic acid, 5-fluorouracil, irinotecan, cetuximab
FOLFOX + cetuximab Folinic acid, 5-fluorouracil, oxaliplatin, cetuximab
FOLFIRI + panitumumab Folinic acid, 5-fluorouracil, irinotecan, panitumumab
FOLFOX + panitumumab Folinic acid, 5-fluorouracil, oxaliplatin, panitumumab
FOLFIRI + aflibercept Folinic acid, 5-fluorouracil, irinotecan, aflibercept
FOLFIRI + bevacizumab Folinic acid, 5-fluorouracil, irinotecan, bevacizumab
Table 2. Drug combinations to treat colorectal cancer.
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Patients’ responses to treatment are limited, and in fact less than one-third of patients respond 
to 5-fluorouracil as a single agent [2, 3]. However, when used in combination, for instance, with 
oxaliplatin-based therapy, 50% response rate is obtained [4]. Resistance to 5-fluorouracil can be 
due to loss of SMAD4 [5], thymidylate synthase (TYMS) amplification [6], defective mismatch 
repair (MMR) genes [7], high level expression of thymidylate synthase (TS) [8], increased DPD 
activity [9], microsatellite instability [9], modulation of the Bcl2 family members [10], cell cycle 
perturbation [11], decreased ATP synthase [12] and adaptation to oxidative stress [13]. General 
mechanisms attributed to oxaliplatin resistance include cellular transport, detoxification, DNA 
repair, cell death, epigenetic alteration and NF-κβ signaling pathway [14].
Although, the use of cetuximab and panitumumab in combination with other agents is very 
effective, they are not sufficiently potent as single agents and are reported to work in only 
around 10% of cases [15]. Over the last decade, a number of papers on anti-epidermal growth 
factor receptor (EGFR) resistance mechanisms have been published [16–18]. Resistance mech-
anisms attributed to EGFR resistance include, but are not limited to, low EGFR gene copy 
number, low expression of AREG and EREG, EGFR S492R mutation, RAS mutation, BRAF 
V600E mutation, PIK3CA exon 20 mutation, PTEN loss, STAT3 phosphorylation, activated 
IGF1R, MET amplification, HER2 amplification, altered VEGF/VEGFR and EMT [16, 19].
Unfortunately, the lack of predictive markers would allow clinicians to select patients who 
are most likely to benefit from a specific therapy remains a challenge. A recent review by Wu 
et al. reported that in the context of metastatic cancer, approximately 90% of treatment failure 
is due to multi-drug resistance [20]. Currently, the only markers that predict potential toxicity 
to 5-FU treatment are DPD deficiency, DPYD mutation, UGT1A1 and high TS expression [21]. 
Moreover, the only marker that predicts lack of response to 5-FU is mismatch repair deficiency 
(dMMR), while pembrolizumab, dMMR predicts increase in response [7]. With respect to anti-
EGFR treatment, KRAS, NRAS and BRAF mutations are the only biological markers that pre-
dict lack of response and hence pose a contraindication to treatment administration [21].
Both intrinsic resistance, which is characterized by cancer cells having only a slight or no 
response to treatment from the beginning, and acquired resistance that is described as, initially, 
having a clinical response, ensued by development of resistance will be discussed [22]. Several 
studies that discuss resistance to specific chemotherapeutic agents have been published and 
therefore we will be solely referring to salient resistance mechanisms to CRC therapies.
2. The classical model of resistance
2.1. Drug metabolism
Chemotherapeutic agents are extensively metabolized by Phase I, Phase II and Phase III 
enzymes. Phase I enzymes, which are mostly involved in chemical modification, include the 
heme protein cytochrome superfamily CYP450, which is sub-divided into 74 gene families 
and is involved in oxidation reactions. CYP3A is involved in irinotecan metabolism while 
CYP2A6, CYP2C8 and CYP1A2 are involved in tegafur activation [23].
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Increased expression of dihydropyrimidine dehydrogenase (DYPD) or thymidine phos-
phorylase (TP) is correlated with resistance to 5-FU chemotherapy [24]. On the other hand, 
in a cohort of 177 CRC patients, there was a correlation between high TP expression and a 
better survival rate in the doxifluridine arm (p = 0.025) [25]. TP has also been reported to 
increase in both hypoxic and hypoglycemic environments, which will be discussed later [26]. 
Furthermore, polymorphic changes in DYPD account for life-threatening adverse effects in 
patients treated with 5-FU or its derivatives [27]. On the other hand, patients having a low 
expression of DYPD cannot metabolize 5-FU efficiently [28]. Decreased orotate phosphoribo-
syl transferase (OPRT) expression in gastric cancer is associated with resistance to 5-FU [29].
Phase II enzymes are involved in conjugation and include glutathione (GSH), glutathione-S-
transferase (GSTs), uridine diphosphate glucuronosyltransferases (UGT) and NADH quinone 
oxidases (NQO). One of the oxaliplatin resistance mechanisms entails elevation of glutathione 
mediated by γ-glutamyl transpeptidase [30]. Additionally, GSTπ1 is associated with oxalipla-
tin and cisplatin resistance mechanisms [31]. SN-38, the active metabolite of irinotecan, is inac-
tivated by way of glucuronidation by UGT [32]. UGT1A1 is one of the main genes involved in 
glucuronidation and is reported as being highly polymorphic; subsequently patients having 
UGT1A1*28 polymorphisms tend to suffer from increased risks of toxicity as reported in a 
cohort of colorectal cancer patients [33]. Both CYP450 and GSTs have been implicated in the 
metabolism of chemotherapeutic agents, but their predictive value is still uncertain [32].
Members of the ATP-binding cassette (ABC) superfamily are involved in Phase III drug 
metabolism [34] and to date 49 ABC transporters have been documented in humans [35]. 
The role of ABC transporters is to use energy from ATP hydrolysis to move their substrates 
across biological membranes and against concentration gradients, thereby limiting cel-
lular accumulation of their substrates [36]. ABC members include P-glycoprotein (MDR1/
ABCB1), breast cancer resistance protein (BCRP/ABCG2) and transporters of the multidrug 
resistance-associated protein (MRP/ABCC) family like the multi-drug resistance protein 5 
(ABCC5), which bestows resistance to 5 FU via transporting the monophosphate metabolites 
in colorectal and breast cancers [37]. MDR1 is found to be highly expressed in the epithelial 
cells of the colon, overexpressed in a number of tumors, and has been associated with treat-
ment failure [38]. At least 12 ABC transporters from 4 ABC sub-families have been shown 
to have a role in in vitro drug resistance (reviewed in Ref. [39]). MRP5 has been reported to 
confer cross-resistance to a number of anti-cancer agents including 5-FU, oxaliplatin and a 
number of antifolates [37]. The authors postulated that resistance might be instigated via 
drug efflux mechanisms which interfere with 5-FU’s ability to impede both DNA and RNA 
synthesis. P-glycoprotein is a drug efflux pump and exerts its mode of action by lowering 
the intracellular concentration of a number of drugs, which subsequently leads to increased 
drug resistance [40]. BCRP is also involved in irinotecan efflux and is reported to be over-
expressed in colon cancer, subsequently increasing chemoresistance.
2.2. Drug targets
5-FU naive CRC patients exhibiting high expression of TS and disturbed folate pools are 
intrinsically resistant to 5-FU [9]. A meta-analysis of over 3000 pooled CRC cases by Popat and 
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colleagues concluded that the variation of TS expression in CRC patients could explain inter-
individual variation in clinical outcome, and patients with low TS expression treated with 
5-FU had better overall survival [41]. CRC patients who are chemoresponsive to 5-FU have 
lower TS enzymatic activity compared to those patients who fail to respond [42]. Furthermore, 
the low availability of 5,10-methylenetetrahydrofolate and its polyglutamates also contrib-
uted to intrinsic resistance [43]. An indirect resistance mechanism reported in hepatocellular 
carcinoma cells is the induction of the expression of the transcription factor Late SV40 Factor 
(LSF) that regulates TS expression, by way of the astrocyte elevated gene-1 (AEG-1) [44].
Additionally, TS mRNA increases in a number of patients treated with 5-FU, resulting in 
acquired resistance [45]. In a review by Holohan et al., the authors explained further that 
5-FU can post-transcriptionally upregulate the TS expression as a result of the inhibition of 
a negative feedback loop where the substrate free TS binds to and inhibits the translation of 
thymidylate synthase mRNA [38].
Watson and colleagues reported that patients with TYMS amplification treated with adjuvant 
chemotherapy had a median overall survival of 18 months shorter when compared to patients 
with low or normal TYMS copy number [46]. A total of 113 mCRC patients were enrolled in 
this study (62 exposed and 51 unexposed to 5-FU prior to resection) and the investigators con-
cluded that TYMS copy number gain was associated with patients treated with 5-FU-based 
neoadjuvant treatment [46].
Guo and colleagues have demonstrated that a possible mechanism of acquired 5-FU resis-
tance can be due to disruption in cell cycle. Using two 5-FU resistant and two sensitive cell 
lines, Guo and colleagues showed that the protein expression of CDK2 (total and phosphory-
lated threonine 160), Cyclin D3, and Cyclin A was significantly decreased in the 5-FU resistant 
cell lines. On the other hand, p21WAF1 expression was modestly increased in both resistant cell 
lines [11]. The authors postulated that the G1 and S phase delay in the 5-FU resistant cell lines 
occurs because of Cyclin E—CDK2 complex deficiency. Additionally, the Cyclin A—CDK2 
complex is also deficient and may assist in bringing about a delay in the S phase of 5-FU resis-
tance cell lines [11]. Guo and colleagues speculated that the slowing down of the cell cycle 
might interfere with the active 5-FU metabolites being incorporated into DNA and also allows 
the cells to repair the DNA damage [11].
Montagut and colleagues confirmed one mechanism of acquired resistance to cetuximab, 
where they showed that an acquired EGFR ectodomain mutation (S492R) prevented the effec-
tive binding of cetuximab to the receptor [47]. On the other hand, overexpression of EGFR in 
CRC has been poorly correlated with response to anti-EGFR therapy [48]. One of the determi-
nants of poor response is because KRAS mutant patients have a constantly activated KRAS, 
irrelevant to the phosphorylation status of EGFR. Fluorescence in situ hybridisation (FISH) 
analysis was carried out on a cohort of 58 mCRC patients treated with panitumumab and it 
was observed that patients that did not exhibit an EGFR copy number gain or chromosome 7 
polysomy or amplification were associated with treatment failure (p = 0.0009, p = 0.0007) [49]. 
Another possible mechanism of resistance using an in vitro model postulated that increased 
Src family kinases activity leads to lengthened EGFR activity, increased EGFR-modulated 
HER3 activity, and activation of the PI3K/AKT pathway [50].
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A study by Lievre and colleagues on a cohort of 30 mCRC patients reported a highly significant 
association between non-response to cetuximab and mutant KRAS (n = 19, p = 0.0003) [51]. This 
association was further confirmed by other larger studies [52, 53]. A study by Misale and col-
leagues unprecedentedly described that a significant number of wild-type KRAS CRC patients, 
who are initially responsive to anti-EGFR therapies, acquire resistance due to de novo KRAS 
mutations resulting from continuing mutagenesis [54]. Another somatic mutation, associated 
with treatment resistance in CRC is PIK3CA [55], is mutated in 25–32% of CRC patients [56].
2.3. DNA damage repair
Mismatch repair deficiency (dMMR) can occur because of both sporadic and hereditary 
CRC. In the autosomal dominant hereditary non-polyposis colon cancer (HNPCC), which 
is also referred to as Lynch Syndrome, dMMR arises primarily due to inactivating germline 
mutations in either MLH1, MSH2, PMS2, or MSH6 [57]. Furthermore, loss of function of the 
remaining allele can occur via various mechanisms, namely loss of heterozygosity, mutations, 
gene conversion, and also promoter methylation [58]. On the other hand, epigenetic hyper-
methylation of MLH1 accounts for the majority of sporadic dMMR in CRC [59]. A recent 
study by Ye and colleagues concluded that miR-1290 promotes 5-FU resistance by directly 
targeting hMSH2 [60].
An in vitro study on CRC cell lines showed that MMR-proficient cell lines were more sensi-
tive to the therapeutic doses of 5-FU (5–10 μM) compared to MMR-deficient cell lines [61]. 
Furthermore, patients who are high microsatellite instable (MSI-H) do not show any survival 
advantage when administered 5-FU-based chemotherapies [62]. The scientific literature not 
only alludes to the fact that dMMR tumor cells have a distinct response to standard chemo-
therapies, but also to many emerging therapies for CRC [58]. In an in vitro study, Tajima and 
colleagues showed that resistance of dMMR cancer cells to 5-FU can arise due to the incorpora-
tion of 5-FU metabolites in DNA [63].
Mechanisms attributed to resistance to oxaliplatin include increased DNA repair, impaired 
DNA adduct formation, over-expression of copper transporters (increased levels of ATP7B 
correlated with poor outcome in CRC patients) [64], enhanced drug detoxification, and 
increased tolerance to DNA damage. While NER and recombination repair mechanisms do 
not distinguish between cisplatin and oxaliplatin adducts, mismatch repair, damage-recogni-
tion proteins, and translesion DNA polymerases do distinguish between the two [65].
Increased excision repair cross complementation group 1 (ERCC1) mRNA expression cor-
relates with resistance to oxaliplatin [66]. A polymorphism (Gln mutant allele) in X-ray repair 
cross complementation group 1 (XRCC1), which is involved in single strand break, adduct 
formation, and base excision repair, was associated with treatment resistance in a cohort of 61 
patients treated with 5-FU and oxaliplatin [67].
2.4. p53
An in vitro study on the NCI-60 panel investigated the relationship between a group of p53 
mutant and p53 wild-type cell lines and chemosensitivity to 123 drugs used in cancer treatment. 
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One of the findings was that the median GI50 for p53 mutant cell lines treated with 5-FU was 
sixfold higher than the GI50 of p53 wild-type cell lines [68].
The TP53 Colorectal Cancer International Collaborative Study published a study consisting 
of a patient cohort of 3583 samples from 25 different research groups in 17 countries. One 
of the aims of this study was to investigate whether there was a prognostic impact of TP53 
mutations and treatment subgroups. In 1334 Dukes’ C patients (792 wild-type TP53 and 542 
mutant TP53), the wild-type TP53 patients treated with chemotherapy showed significantly 
better survival in the proximal and rectal tumor groups (p = 0.006 and p = <0.001, respectively) 
and a trend towards statistical significance (p = 0.022) was observed for the distal tumor group 
[69]. In the mutant TP53 group, patients receiving chemotherapy had better survival only in 
the proximal colon group (p = <0.001), with the authors concluding that TP53 mutation had 
no predictive value within Dukes’ C patients treated by surgery alone or surgery and chemo-
therapy [69]. The authors advised caution in interpreting these observations, since the chemo-
therapy treatment was not always 5-FU based. When the 5-FU-based regimens were grouped 
together, the authors reported that chemotherapy can have an impact on survival based on 
TP53 mutational status and tumor sites [69]. Furthermore, this study showed that wild-type 
TP53 rectal patients received a significant survival benefit from 5-FU-based chemotherapy, 
irrespective of whether or not radiotherapy was received [69].
In 2008, Ahmed and colleagues carried out a study on 41 Dukes’ C CRC patients that had a 
curative resection of the primary tumor and were administered 5-FU adjuvant treatment. The 
p53 mutation status was confirmed by gene sequencing and the study concluded that there 
was significant advantage for the wild type p53 patients in the time to develop metastasis and 
overall survival within the two groups receiving 5-FU adjuvant treatment [70].
2.5. Apoptosis
Failure of cells to undergo apoptosis may affect treatment efficacy [71]. Apoptosis can occur 
via two main signaling pathways: extrinsic (receptor-mediated pathway) and/or intrinsic 
(mitochondrial-mediated pathway [72]. Although a number of studies have reported the 
involvement of extrinsic pathway in treatment resistance, namely CD95 (Fas), it has been 
shown that under certain situations most chemotherapy-treated cells undergo intrinsic apop-
tosis [71, 73].
By way of an in vitro model, Gourdier and colleagues demonstrated that acquired resistance 
to oxaliplatin can occur via a defect in the intrinsic apoptosis pathway [74]. Furthermore, 
expression of cleaved caspase-3 and Bax was lost in the 68-fold oxaliplatin-trained resistant 
cell line, while the expression of Bcl-2, Bak, and Bcl-XL remained unaltered, suggesting that they are not involved in the acquired resistance mechanism to oxaliplatin [74]. Transcription 
factor NFκβ is known to be constitutively activated in colorectal cancers and although it has 
been associated with pro-apoptotic function, it is not always the case [75]. 5-FU has been 
shown to induce NFκβ expression via IKKβ and consequently chemoresistance in colorectal 
cell lines [76]. Apart from the fact that oxaliplatin, like 5-FU, can cause NFκβ constitutive acti-
vation, this activation imparts chemoresistance via c-FLIP and Mcl-1 [77].
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A study identified double stranded RNA dependent protein kinase (PKR), as a key molecule 
in inducing apoptosis in colon cancer cells—irrelevant of the p53 status [78]. The authors 
proceeded by demonstrating that PKR knockdown cells responded poorly to treatment with 
5-FU. The importance of integrins and apoptosis in chemoresistance is being investigated 
by a number of groups. A study by Liu and colleagues focussed on the involvement of the 
β6-integrin-ERK-MAP kinase pathway in conferring chemoresistance to 5-FU in colon cancer 
lines (Figure 1) [79].
3. Novel resistance mechanisms
3.1. Warburg effect
Over the past decade, the significance of the Warburg effect in the field of oncology has gained 
momentum and a number of original research papers [80, 81] and reviews have been pub-
lished on this topic [82]. The Warburg effect, also referred to as the glycolytic phenotype, is 
singularized by an increased rate of aerobic glycolysis together with irreversible injury to 
mitochondrial oxidative phosphorylation [83] and is favored by the majority of tumors [84]. 
Subsequently, Tong and colleagues showed that aerobic glycolysis is involved in cancer cell 
proliferation and tumorigenesis in a model of HCT116 colorectal cell lines [85]. A number of 
mechanisms that affect increased glycolysis, and therefore contribute to the Warburg effect, 
include mitochondrial defects, adaptation to hypoxic conditions, oncogenic signals, and 
altered metabolic enzymes [86]. A number of these mechanisms occur via hypoxia inducible 
factor-1 (HIF-1) [87].
Figure 1. Treatment for colorectal cancer patients according to the stage at diagnosis.
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A putative major player in the Warburg effect and cancer is the uncoupling protein coding-2 
(UCP2) [88]. UCP2 is located in the mitochondrial inner membrane and its main function is 
that of a mitochondrial transporter protein, that creates proton leaks across the inner mito-
chondrial membrane, ergo uncoupling oxidative phosphorylation from ATP synthesis [89]. 
Furthermore, UCP2 might act as a negative regulator of ROS production [90].
Horimoto et al. postulated that UCP2 is involved in colon tumor adaptation and is correlated 
with neoplastic changes [91]. UCP2 gene expression and protein expression was assessed on 
a small cohort of 10 patients, where a paired normal and tumor sample for each patient was 
processed. Gene expression results demonstrated an average of 3.88 ± 0.85-fold difference 
in UCP2 mRNA expression between the tumor (T) and peritumoral (P) paired samples. The 
same ratio was found for UCP2 protein expression and furthermore a strong linear correlation 
between T/P ratio of UCP mRNA and protein expression (r = 0.91, p = 0.0015) was confirmed. 
Additionally, immunohistochemistry (IHC) for UCP2 was carried out on a cohort of 9 hyper-
plastic polyps, 17 adenomas, and 107 adenocarcinoma and positive scores were 11.1, 58.8, and 
86%, respectively.
A comparable study was undertaken on a larger cohort of colon cancer patients and it yielded 
the same results and correlations in addition to association of UCP2 expression and metas-
tasis [88]. Altered colon cancer metabolism, as confirmed through measurement of UCP2 
expression in these studies, can also contribute to resistance to cancer therapies. An in vitro 
study investigated the rate of cell death caused by 5-FU, with respect to different metabolic 
rates, as quantified by the bioenergetic signature [92]. This study demonstrated the bioener-
getic signature directly correlates with the apoptotic response to treatment with 5-FU [92].
Tumor adaptation to hypoxic and acidic microenvironments strongly selects for tumor cells 
that are resistant to chemo- and radiotherapy [93]. The slowing down of cell cycling induces 
a decreased rate of cell division, thereby decreasing chemotherapy activity [93]. Furthermore, 
hypoxia dysregulates several DNA damage response pathways and prevents effective func-
tioning of proteins involved in homologous recombination (HR), non-homologous end join-
ing (NHEJ), and the mismatch repair (MMR) pathways, thereby driving genetic instability 
[94]. The cascade of events triggered by chronic hypoxia may also bring about amplification 
of multidrug resistant gene ABCB1 via induction of chromosomal fragile sites [94].
An in vitro study on colon carcinoma cell lines demonstrated that low oxygen concentration 
resulted in decreased protein expression of Bid, Bad, and Bax [87]. A further series of exper-
iments illustrated that all three CRC cell lines studied expressed a functional HIF-1 path-
way and the authors showed that in a hypoxic environment Bid down-regulation occurs via 
HIF-1, while down-regulation of Bax and Bad occurs independently of HIF-1 function [87]. 
Additionally, under anoxic conditions, SW480, HCT116, and HT29 were resistant to etopo-
side treatment and SW480 was also resistant to oxaliplatin. Further investigation by Erler and 
colleagues demonstrated that down regulation of Bid and/or Bax contributed to etoposide 
resistance in this model [87]. An important observation from this study was that Bak was least 
responsive to hypoxia and thereby it might be crucial for drug-induced apoptosis [87].
The PI3K/Akt signaling pathway enhances aerobic glycolysis, and dual PI3K/mTOR inhibi-
tors can influence the cancer cell metabolic programme [95]. Oncogenic mutations involving 
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this pathway, MAPK, and Src pathways have been shown to increase HIF-1 expression in 
both hypoxic and normoxic conditions [96]. Inhibiting HIF1 decreases proliferation, influ-
ences anaerobic glycolysis, encourages apoptosis, and reduces resistance to chemo- and 
radiotherapy [93].
Moderate evidence in the literature demonstrates that 18q LOH/SMAD4 loss has potential 
for it being used as a marker to predict response to 5-FU-based therapies [97]. Papageorgis 
and colleagues demonstrated that a SMAD4 defect suppresses hypoxia-induced cell death, 
induces aerobic glycolysis, and promotes 5-FU resistance in the HCT116 cell line model [98]. 
Furthermore, the authors observed a physical interaction between SMAD4 and HIF1α and 
postulated that the acquired chemoresistance in 18q-deficient CRC may be explained by 
Smad4 negatively regulating HIF1α-induced GLUT1 expression and the rate of aerobic gly-
colysis [98]. Other oncogenes/tumor suppressor genes known to be involved in the stimula-
tion of glycolytic energy include Ras, c-myc, Src, and p53 [99].
Downregulation of pyruvate kinase M2 (PKM2) is also known to promote the Warburg effect 
metabolic phenotype and tumorigenesis [80]. Additionally, PKM2 is a HIF-1 target gene and 
concurrently a co-activator of HIF-1 [93]. A study by Tamada and colleagues on a number of 
cancer cell lines, which also comprised of CRC cell lines HCT116 p53 wild-type and HCT116 
p53 null, demonstrated CD44-regulated glycolysis in p53 deficient cells via interaction with 
PKM2 [100]. Furthermore, the authors speculated that CD44 functions as a scaffold between 
a tyrosine kinase and PKM2 near the cell membrane, ergo down-regulating the activity of 
PKM2 [100]. By means of a set of elegant experiments, the authors showed evidence that 
CD44 silencing in p53 deficient cell lines sensitized the cells to cisplatin, 5-FU, and adriamy-
cin in normoxia, and that CD44 silencing of p53 wild-type cells under hypoxic conditions 
increased sensitivity to these three chemotherapeutic agents [100].
The relationship of hypoxia and resistance to both radio- and chemotherapy has been explored 
for the last decade and several mechanisms have been postulated. As evidenced by a number 
of studies referred above, the Warburg effect is an adaptive mechanism used by solid tumors 
to overcome stress caused by hypoxia and also contributes to resistance to both chemotherapy 
and targeted inhibitors.
3.2. Clonal evolution
Another contributor to therapy failure is the innate Darwinian aspect of cancer [101]. In a 
review of clonal evolution, Greaves and Maley describe the complexity of cancer and the 
selective pressure for resistant cells to thrive when treated with chemotherapeutic agents. 
Similarly, adaptive microenvironmental mechanisms such as hypoxia and acidosis lead 
to both phenotypic and genotypic heterogeneity [102]. This evolution not only affects the 
genomic instability of the tumor but also contributes towards resistance to therapy, including 
targeted therapies [102].
A retrospective study analyzing circulating tumor DNA from a cohort of 28 mCRC patients 
suggested that development of resistance to panitumumab can occur in metastatic lesions, 
having a sub-clone encompassing just 1 of 42 mutations associated with resistance to panitu-
mumab. Subsequently, the time for recurrence is basically the time taken for that sub-clone to 
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repopulate the lesion [103]. Furthermore, the authors concluded that resistance mutation in 
KRAS and other genes were likely to be present prior to starting panitumumab therapy [103].
A number of mechanisms contributing to acquired resistance to 5-FU-based therapies include 
alteration of the drug’s specific target, drug inactivation, influx and efflux of drugs in the 
cells, drug-induced damage, and evasion of apoptosis [104]. In an attempt to comprehend 
these complex mechanisms, Tentes et al. investigated 5-FU acquired resistance in the SW620 
cell line model [105]. A significant finding reported in this study consisted of the maintenance 
of a 5-FU resistant phenotype, albeit by culturing the trained cell line in drug-free media 
for 15 weeks. The authors concluded that the resistant clones may have acquired an altered 
genetic background and unique gene expression patterns due to long-term exposure to 5-FU, 
and that this scenario might explain relapses caused by residual disease of chemo-resistant 
cells. Besides, overlapping mechanisms of resistance to 5-FU could be observed in the trained 
resistant cell line [105].
3.3. Intra-tumor heterogeneity
A published study evidenced that intra-tumor heterogeneity is a considerable hurdle to both 
predictive and prognostic biomarker development [106]. One of the principal results in this 
study highlighted that 63–69% of all somatic mutations are not detectable across every tumor 
area, hence confirming that one biopsy is not representative of the whole tumor [106]. Intra-
tumor heterogeneity is one of the main challenges to patients being successfully treated and 
can also contribute to patients having relapses [107].
Chromosomal instability (CIN) is associated with both intrinsic- and acquired-drug resistance 
and also involved in intra-tumor heterogeneity [108]. A number of hypotheses surrounding 
CIN, Darwinian selection, and intra-tumoural heterogeneity are currently being investigated. 
Evidence has been obtained to indicate that cells having a high degree of chromosomal insta-
bility are more predisposed to exhibit intrinsic resistance [108].
Lee and colleagues conducted a study on a panel of 27 CRC cell lines (18 of which were 
CIN+) and demonstrated that CIN+ cell lines were significantly more intrinsically resistant to 
the inhibitors used (Kolmogorov-Smirnov test p < 0.0001) and, even at similar proliferation 
rates, CIN+ cell lines were more resistant to treatment when compared to CIN− (one sided 
Wilcoxon-Mann-Whitney test, p = 0.049) [55]. Furthermore, according to previous reports, 
patients treated with 5-FU-based therapy who exhibited CIN+ did not obtain as much benefit 
from the treatments, when compared to patients having diploid CRC [109]. This acquired 
multidrug resistance has been attributed to cell heterogeneity due to multiple chromosomal 
re-assortments in these aneuploid cells [55]. One of the hypotheses that Lee and colleagues 
discussed is that there is a distinct CIN+ survival phenotype that triggers an endurance to 
ongoing chromosomal rearrangements which is also related to drug resistance [55].
Phenotypic heterogeneity arises from both genetic and non-genetic influences [110]. Non-
genetic influences can emerge from phenotypic plasticity and differentiation of cancer stem 
cells [107]. The cellular phenotype is affected by several factors namely, stochastic fluctua-
tions (noise), genotypes, microenvironment, and the gene regulatory network [110]. In their 
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review, Marusyk and colleagues remark that even though genetic heterogeneity is not likely 
to contribute considerably to phenotypic heterogeneity, it still supports tumor evolution 
during tumorigenesis and treatment resistance [110]. Phenotypic heterogeneity manifests as 
phenotypic diverse subpopulations of subpopulation of tumor cells, histologic alterations, 
different patterns of disease progression, prognosis, diagnosis, and also responses to therapy 
[111]. This necessitates further investigations on therapeutic resistance of CRC with respect to 
phenotypic heterogeneity.
3.4. Pharmacoepigenomics
Epigenetic modifications are implicated in the progression of chemoresistance [112]. They 
bring about changes in gene expression that are autonomous of changes in DNA sequence 
and persevere over numerous cell divisions. In contrast to genetic modifications, epigenetic 
transformations are reversible [113]. As a result, the field of pharmacoepigenomics is now 
gaining more popularity. One of the main mechanisms of action of chemotherapeutic agents is 
by inducing DNA damage which subsequently leads to either DNA repair, apoptosis, or cell-
cycle arrest [114]. A number of genes implicated in these biological processes in cancer cells 
are epigenetically regulated [115]. Drug resistance has been associated with hypermethyl-
ation of promoter regions of pro-apoptotic genes, hypomethylation of drug efflux promoters, 
and also modified promoter methylation patterns of DNA repair genes [116]. Furthermore, 
global histone modification patterns may also be involved in drug resistance [117].
Sugita and colleagues conducted a study on a cohort of 80 gastric cancer patients and inves-
tigated the relationship between methylation of BNIP3 and DAPK with respect to response 
to 5-FU-based therapy. This study confirmed a relationship between poor response rate and 
methylation of one or both genes when compared to patients that did not have methyla-
tion (p = 0.003) [118]. Furthermore, a study on 112 primary colorectal patients substantiated 
that BNIP3 is methylated in CRC patients, with approximately 58% of the cohort exhibiting 
methylation [119]. Additionally, 30 patients having BNIP3 methylation were non-responsive 
to irinotecan therapy [119]. An in vitro study demonstrated that cells having a methylated 
p16Ink4A were more resistant to irinotecan-induced cell cycle arrest [120] . Cheetham and col-
leagues presented support that hypermethylation of the SPARC promoter is frequently found 
in both CRC tumor and cell lines when compared to normal colon (p = 0.03) [121]. A previous 
in vitro study by the same group showed that mRNA and protein expression of SPARC were 
low in chemoresistant tumors and thereby the authors concluded that hypermethylation of 
the SPARC promoter might be a potential mechanism of low SPARC expression, leading to 
resistance to therapy [121, 122].
Dynamic chromatin modification can also influence resistance to treatment and a publication 
by Sharma and colleagues illustrated this resistance mechanism. “Drug-tolerant persisters” 
were detected while studying the acute response of human cell lines with respect to different 
treatments. These cells remained viable in conditions where other cells failed to thrive, and 
since they were encountered at a higher frequency than expected, the authors associated this 
observation to epigenetic regulation [123]. Following several elegant experiments, the authors 
concluded that this transiently acquired drug resistant phenotype is capable of arising de novo 
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and requires the histone demethylase KDM5A/RBP2/Jarid1A. This particular histone demeth-
ylase secures a metastable chromatin state which contributes towards the ability of cells to 
tolerate drug exposure. Additionally, this chromatin state is dependent on IGF-1R signaling, 
which has also been associated with drug resistance in a number of other studies [124, 125].
3.5. Additional mechanisms
Resistance to the newest drug, trifluridine was attributed to decreased changes in expression 
of mRNA and miRNA located on chromosome 9. This could have been due to either genome 
deletion or LOH of let-7d-5p, a miRNA inversely associated to trifluridine-induced prolifera-
tive effects; hence low expression would lead to decreased effectiveness [126] .
Resistance-promoting adaptive responses include the (1) epithelial-mesenchymal transition 
(EMT) which is associated with invasive capacity, increased motility and related to chemo-
therapy, and targeted therapy resistance [38]; (2) Oncogenic bypass and pathway redundancy, 
also referred to as compensatory signaling pathway via crosstalk mechanisms is involved in 
acquired resistance to cetuximab. With EGFR deregulated, HER2, HER3, cMET, MAPK, and 
Akt are subsequently switched on and as a result, acquired resistance can ensue since some 
RTKs share signaling pathways involved in proliferation and survival [127]. (3) Activation 
of pro-survival signaling: ADAM17, known to be deregulated in CRC, is also known to be 
activated with chemotherapy and has been implicated with growth factor shedding, growth 
factor receptor activation, and drug resistance [128].
Another downstream resistance mechanism is autophagy. In CRC, BRAF V600E induces 
autophagic properties. Recently, Goulielmaki and colleagues reported that PI3K/AKT/MTOR 
inhibitors induce autophagic tumor properties, whereas RAF/MEK/ERK signaling inhibitors 
reduce expression of autophagic markers. They showed that pre-treatment of autophagy 
inhibitor 3-MA followed by its combination with BRAFV600E targeting drug PLX4720 can 
synergistically sensitize resistant colorectal tumors [129].
Another recent review highlighted the involvement of telomerase in drug resistance in cancer 
[130]. The main telomerase-related mechanism highlighted in this review included hTERT translo-
cation, hTERT and cell resistance to stress, G-quadruplex inhibitors specific, telomerase inhibition 
and the mechanism by which telomerase helps cancer cells resistance to DNA damage/apoptosis. 
Recent literature also implicates the mammalian vault complexes in drug resistance [130].
4. Conclusion
During the last decade, a number of groups have started taking a systems medicine 
approach to better understand treatment resistance in colorectal cancer. As described by 
the Coordinating Action Systems Medicine, this approach comprises the iterative and 
reciprocal feedback between clinical investigations and practice with computational, sta-
tistical and mathematical multi-scale analysis and modeling of pathogenic mechanisms, 
disease progression and remission, disease spread and cure, treatment responses and 
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adverse events, as well as disease prevention both at the epidemiological and individual 
patient level [131].
We are already witnessing a number of success stories and by integrating data, especially 
with respect to understanding mechanisms of resistance, we are now moving away from 
clinical trials directed to specific tumors towards umbrella trials (multiple molecular targets 
in a single tumor) and basket trials (single molecular abnormality across multiple cancer 
types). This evolution can be clearly seen in CRC, where we started with one gene, one drug 
approach, and moved towards a multi-gene, multi-drug approach and currently we are at a 
multi-molecular, multi-drug approach [132].
This systems medicine approach is helping to accelerate bench to bedside developments and 
an example is the EXACT trial, where treatment-refractory cancer patients are administered 
an individualized treatment concept based on prospective biomarkers assessed in a real-time 
biopsy [133].
All of the above has had a major impact on the clinic and as we can now witness, we have 
achieved a better patient stratification, earlier and more sensitive diagnostics and drug repur-
posing. Nonetheless, it is important that we continue working to overcome the major chal-
lenges we are still facing. These include, but are not limited to morphologic and molecular 
heterogeneity of cancer, treatment resistance, drug addiction, and other challenges such as 
standardization of methods, infrastructure, and cost and big data. Hence, it will be important 
to have appropriate biomarkers to inform clinicians on administering the most effective treat-
ment to the individual patient at the right time.
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